The introduction of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the medical community. This innovative dual GIP and GLP-1 receptor medication suggests to deliver impressive improvements in body reduction compared to current therapies. Preliminary patient tr